收费全文 | 113039篇 |
免费 | 10870篇 |
国内免费 | 6150篇 |
耳鼻咽喉 | 702篇 |
儿科学 | 3080篇 |
妇产科学 | 1291篇 |
基础医学 | 9947篇 |
口腔科学 | 1218篇 |
临床医学 | 10253篇 |
内科学 | 22238篇 |
皮肤病学 | 909篇 |
神经病学 | 2395篇 |
特种医学 | 5484篇 |
外国民族医学 | 66篇 |
外科学 | 14573篇 |
综合类 | 20230篇 |
现状与发展 | 38篇 |
预防医学 | 3895篇 |
眼科学 | 632篇 |
药学 | 9747篇 |
72篇 | |
中国医学 | 6161篇 |
肿瘤学 | 17128篇 |
2024年 | 351篇 |
2023年 | 2043篇 |
2022年 | 3890篇 |
2021年 | 4980篇 |
2020年 | 4456篇 |
2019年 | 3843篇 |
2018年 | 3646篇 |
2017年 | 4171篇 |
2016年 | 4871篇 |
2015年 | 4773篇 |
2014年 | 7281篇 |
2013年 | 7268篇 |
2012年 | 6434篇 |
2011年 | 7166篇 |
2010年 | 5681篇 |
2009年 | 5602篇 |
2008年 | 5635篇 |
2007年 | 5882篇 |
2006年 | 5553篇 |
2005年 | 4745篇 |
2004年 | 3960篇 |
2003年 | 3397篇 |
2002年 | 3085篇 |
2001年 | 2800篇 |
2000年 | 2313篇 |
1999年 | 2016篇 |
1998年 | 1809篇 |
1997年 | 1635篇 |
1996年 | 1446篇 |
1995年 | 1277篇 |
1994年 | 1143篇 |
1993年 | 907篇 |
1992年 | 800篇 |
1991年 | 658篇 |
1990年 | 559篇 |
1989年 | 492篇 |
1988年 | 472篇 |
1987年 | 388篇 |
1986年 | 318篇 |
1985年 | 381篇 |
1984年 | 340篇 |
1983年 | 215篇 |
1982年 | 274篇 |
1981年 | 228篇 |
1980年 | 176篇 |
1979年 | 167篇 |
1978年 | 140篇 |
1977年 | 109篇 |
1976年 | 120篇 |
1975年 | 48篇 |
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.
DLM, CPM and TPM were metabolised by human CYP2B6 and CYP2C19, with the highest apparent intrinsic clearance (CLint) values for pyrethroid metabolism being observed with CYP2C19. Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5. None of the pyrethroids were metabolised by CYP2A6, CYP2E1, CYP3A7 or CYP4A11.
DLM, CPM and TPM were metabolised by both human CES1 and CES2 enzymes.
Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol. TPM had the highest and CPM the lowest apparent CLint values for total metabolism (CYP and CES enzymes) per gram of adult human liver.
Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.